What is he best known for?
The fields of study he is best known for:
Yiwei Li mainly focuses on Cancer research, Cancer, Cancer stem cell, Cell growth and Internal medicine.
His studies deal with areas such as Epithelial–mesenchymal transition, Metastasis, Genistein, Pancreatic cancer and Cancer cell as well as Cancer research.
In his study, Cell cycle is inextricably linked to Carcinogenesis, which falls within the broad field of Cancer cell.
His research on Cancer often connects related topics like Pharmacology.
His Cancer stem cell research includes elements of microRNA, CD44 and Cellular differentiation.
The study incorporates disciplines such as Apoptosis, Notch 1, Signal transduction, Notch signaling pathway and Prostate cancer in addition to Cell growth.
His most cited work include:
- Up-regulation of miR-200 and let-7 by Natural Agents Leads to the Reversal of Epithelial-to-Mesenchymal Transition in Gemcitabine-Resistant Pancreatic Cancer Cells (571 citations)
- Acquisition of Epithelial-Mesenchymal Transition Phenotype of Gemcitabine-Resistant Pancreatic Cancer Cells Is Linked with Activation of the Notch Signaling Pathway (505 citations)
- Multi-targeted therapy of cancer by genistein (437 citations)
What are the main themes of his work throughout his whole career to date?
Yiwei Li mostly deals with Cancer research, Cancer, Cell growth, Cancer stem cell and Internal medicine.
He has included themes like Pancreatic cancer, Cancer cell, Apoptosis, microRNA and Metastasis in his Cancer research study.
His Cancer study integrates concerns from other disciplines, such as Genistein, Immunology, Isoflavones, Pharmacology and Programmed cell death.
His studies deal with areas such as Notch 1, Signal transduction, Cell biology, Cell cycle and Prostate cancer as well as Cell growth.
His work carried out in the field of Cancer stem cell brings together such families of science as Epithelial–mesenchymal transition, CD44 and Cellular differentiation.
As part of one scientific family, Yiwei Li deals mainly with the area of Internal medicine, narrowing it down to issues related to the Endocrinology, and often Diindolylmethane.
He most often published in these fields:
- Cancer research (67.82%)
- Cancer (42.08%)
- Cell growth (28.71%)
What were the highlights of his more recent work (between 2012-2021)?
- Cancer research (67.82%)
- microRNA (21.29%)
- Cancer (42.08%)
In recent papers he was focusing on the following fields of study:
His primary scientific interests are in Cancer research, microRNA, Cancer, Cancer stem cell and Pancreatic cancer.
His study in Cancer research is interdisciplinary in nature, drawing from both CD44, Cell growth, Cancer cell, Signal transduction and Metastasis.
His microRNA research is multidisciplinary, incorporating perspectives in Bioinformatics, Carcinogenesis, Cell biology, Hedgehog and Epigenetics.
His Cancer research includes themes of Inflammation, Oxidative stress, Nuclear export signal and Pharmacology.
His Cancer stem cell research is multidisciplinary, relying on both Epithelial–mesenchymal transition, Tumor progression, Prostate cancer and Oncology.
His Pancreatic cancer research is included under the broader classification of Internal medicine.
Between 2012 and 2021, his most popular works were:
- Down-regulation of miR-221 inhibits proliferation of pancreatic cancer cells through up-regulation of PTEN, p27(kip1), p57(kip2), and PUMA. (123 citations)
- Targeted regulation of Pi3K/Akt/mTOR/NF-κB signaling by indole compounds and their derivatives: Mechanistic details and biological implications for cancer therapy (97 citations)
- Pancreatic cancer stem cells: emerging target for designing novel therapy (96 citations)
This overview was generated by a machine learning system which analysed the scientist’s
body of work. If you have any feedback, you can
contact us
here.
